GSK Advair Set To Surpass Paxil Sales With Label Change, New Indication
Executive Summary
GlaxoSmithKline's Advair Diskus combination asthma agent is expected to surpass Paxil as the company's top-selling product within the next few years, GSK CEO J.P. Garnier told analysts in London